Analysts expect that G1 THERAPEUTICS (NASDAQ:GTHX) will announce earnings of ($0.68) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for G1 THERAPEUTICS’s earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.45). The company is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that G1 THERAPEUTICS will report full-year earnings of ($2.19) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($2.36) per share, with EPS estimates ranging from ($2.41) to ($2.31). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for G1 THERAPEUTICS.

Several brokerages have issued reports on GTHX. Wedbush began coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “outperform” rating and a $31.00 price target for the company. J P Morgan Chase & Co began coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “overweight” rating and a $23.00 price target for the company. Needham & Company LLC began coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued a “buy” rating and a $34.00 price target for the company. Finally, Cowen and Company began coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “outperform” rating and a $31.00 price target for the company.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) traded up 1.08% during midday trading on Thursday, reaching $16.90. The company’s stock had a trading volume of 8,272 shares. The company’s market cap is $476.50 million. The stock has a 50-day moving average of $17.50 and a 200 day moving average of $17.50. G1 THERAPEUTICS has a 12 month low of $13.35 and a 12 month high of $20.60.

ILLEGAL ACTIVITY NOTICE: “G1 THERAPEUTICS (GTHX) Expected to Announce Earnings of -$0.68 Per Share” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/03/g1-therapeutics-gthx-expected-to-announce-earnings-of-0-68-per-share-updated-updated-updated-updated.html.

In other G1 THERAPEUTICS news, Director Fredric N. Eshelman purchased 300,000 shares of the stock in a transaction on Monday, May 22nd. The stock was bought at an average cost of $15.00 per share, for a total transaction of $4,500,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Clay Thorp purchased 133,333 shares of the stock in a transaction on Monday, May 22nd. The stock was acquired at an average price of $15.00 per share, with a total value of $1,999,995.00. The disclosure for this purchase can be found here. Insiders acquired 833,333 shares of company stock valued at $12,499,995 over the last 90 days.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Get a free copy of the Zacks research report on G1 THERAPEUTICS (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related stocks with our FREE daily email newsletter.